Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leukemia × eryaspase × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1

Interventions

Cyclophosphamide 154 Cytarabine 95 fludarabine phosphate 84 Methotrexate 78 Busulfan 73 Filgrastim 66 Rituximab 65 Peripheral Blood Stem Cell Transplantation 53 Etoposide 51 Radiotherapy 49 Cyclosporine 49 Antilymphocyte Serum 48 Mycophenolic Acid 46 fludarabine 44 Tacrolimus 41 Vincristine 40 Whole-Body Irradiation 38 Melphalan 38 Dexamethasone 33 Methylprednisolone 31 Imatinib Mesylate 30 Granulocyte Colony-Stimulating Factor 28 Daunorubicin 28 sargramostim 27 Alemtuzumab 26 Mercaptopurine 24 Azacitidine 23 Idarubicin 22 Doxorubicin 22 Prednisone 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed

123 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡